Dr Andrew Bassett | Head of Research - Cellular Operations

Bassett, Andrew

Andrew leads the Human Gene Editing R&D group at the Wellcome Sanger Institute.  After obtaining his PhD at the MRC-LMB with Andrew Travers on chromatin remodelling in heterochromatin formation, his postdoctoral work focused on the role of small RNAs in targeting chromatin modifications with David Baulcombe in Cambridge, and the function of long non-coding RNA molecules with Chris Ponting and Ji-Long Liu at the MRC-FGU in Oxford. Here he was one of the first to develop CRISPR in Drosophila. He then set up Genome Engineering Oxford at the Dunn School of Pathology, and was involved in projects including the production of sgRNA libraries, and development of methods to investigate miRNA target site functionality in vivo. He has subsequently applied genome editing to different species, the modification of the epigenetic and transcriptional status of a cell, and developed methods to improve the efficiency and specificity of the technology. He is continuing to develop genome engineering techniques in human pluripotent stem cells, with a particular interest in understanding regulation of gene expression in development and neurodegenerative disease including the design and application of a variety of pooled and arrayed CRISPR screening approaches.


  • Editing the Genome of Human Induced Pluripotent Stem Cells Using CRISPR/Cas9 Ribonucleoprotein Complexes.

    Bruntraeger M, Byrne M, Long K and Bassett AR

    Methods in molecular biology (Clifton, N.J.) 2019;1961;153-183

  • Predicting the mutations generated by repair of Cas9-induced double-strand breaks.

    Allen F, Crepaldi L, Alsinet C, Strong AJ, Kleshchevnikov V et al.

    Nature biotechnology 2018

  • In situ functional dissection of RNA cis-regulatory elements by multiplex CRISPR-Cas9 genome engineering.

    Wu Q, Ferry QRV, Baeumler TA, Michaels YS, Vitsios DM et al.

    Nature communications 2017;8;1;2109

  • Alpha-synuclein induces the unfolded protein response in Parkinson's disease SNCA triplication iPSC-derived neurons.

    Heman-Ackah SM, Manzano R, Hoozemans JJM, Scheper W, Flynn R et al.

    Human molecular genetics 2017;26;22;4441-4450

  • Editing the genome of hiPSC with CRISPR/Cas9: disease models.

    Bassett AR

    Mammalian genome : official journal of the International Mammalian Genome Society 2017;28;7-8;348-364

  • Precision Modulation of Neurodegenerative Disease-Related Gene Expression in Human iPSC-Derived Neurons.

    Heman-Ackah SM, Bassett AR and Wood MJ

    Scientific reports 2016;6;28420

  • A genome-wide CRISPR library for high-throughput genetic screening in Drosophila cells.

    Bassett AR, Kong L and Liu JL

    Journal of genetics and genomics = Yi chuan xue bao 2015;42;6;301-9

  • Understanding functional miRNA-target interactions in vivo by site-specific genome engineering.

    Bassett AR, Azzam G, Wheatley L, Tibbit C, Rajakumar T et al.

    Nature communications 2014;5;4640

  • Mutagenesis and homologous recombination in Drosophila cell lines using CRISPR/Cas9.

    Bassett AR, Tibbit C, Ponting CP and Liu JL

    Biology open 2014;3;1;42-9

  • Highly efficient targeted mutagenesis of Drosophila with the CRISPR/Cas9 system.

    Bassett AR, Tibbit C, Ponting CP and Liu JL

    Cell reports 2013;4;1;220-8

Bassett, Andrew